P/B
2,5
Larimar Therapeutics
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
$319.4M
Market Cap • 9/25/2026
2005
(21 years)
Founded
2020
(6 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
1,4
EPS
—
Market Cap
Market Cap
319,4M
EV
168,1M
EV/Revenue
0
EV/EBITDA
-0,9
EV/EBIT
-0,9
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-54,1%
Total Yield
-54,1%
Payout
0%
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
2,2%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
29,4%
CAGR Net Income 5Y
28,5%
CAGR EPS 5Y
-8,7%
CAGR OCF 5Y
29,3%
Leverage
N.D./EBITDA
0,8
Debt/Equity
0%
Current Ratio
4,7
Quick Ratio
4,6
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!